BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 10762127)

  • 1. The spectrum of levodopa-induced dyskinesias.
    Fahn S
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S2-9; discussion S9-11. PubMed ID: 10762127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
    Luquin MR; Scipioni O; Vaamonde J; Gershanik O; Obeso JA
    Mov Disord; 1992; 7(2):117-24. PubMed ID: 1350058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dyskinesia caused by L-DOPA].
    Derkinderen P; Vidailhet M
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dyskinesias and the subthalamic nucleus.
    Benabid AL; Benazzouz A; Limousin P; Koudsie A; Krack P; Piallat B; Pollak P
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S189-92. PubMed ID: 10762147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical physiology of dopa dyskinesia.
    Hallett M
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S147-50; discussion S150-3. PubMed ID: 10762142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations.
    de la Fuente-Fernández R
    Clin Neuropharmacol; 1999; 22(4):216-9. PubMed ID: 10442251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment.
    Crossman AR
    Mov Disord; 1990; 5(2):100-8. PubMed ID: 1970120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
    Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y
    Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model.
    Obeso JA; Rodriguez-Oroz MC; Rodriguez M; DeLong MR; Olanow CW
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S22-32; discussion S32-4. PubMed ID: 10762129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing levodopa-induced dyskinesias.
    Olanow CW; Obeso JA
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S167-76; discussion S176-8. PubMed ID: 10762145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease.
    Brotchie JM
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S105-12; discussion S112-4. PubMed ID: 10762137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical treatment of levodopa-induced dyskinesias.
    Rascol O
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S179-88. PubMed ID: 10762146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease.
    Alonso-Frech F; Zamarbide I; Alegre M; Rodríguez-Oroz MC; Guridi J; Manrique M; Valencia M; Artieda J; Obeso JA
    Brain; 2006 Jul; 129(Pt 7):1748-57. PubMed ID: 16684788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?
    Bejjani BP; Arnulf I; Demeret S; Damier P; Bonnet AM; Houeto JL; Agid Y
    Ann Neurol; 2000 May; 47(5):655-8. PubMed ID: 10805339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction.
    Bennett JP; Landow ER; Dietrich S; Schuh LA
    Mov Disord; 1994 Jul; 9(4):409-14. PubMed ID: 7969207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgery for levodopa-induced dyskinesias.
    Lang AE
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S193-9; discussion S199-202. PubMed ID: 10762148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical aspects of motor fluctuations in Parkinson's disease.
    Poewe WH
    Neurology; 1994 Jul; 44(7 Suppl 6):S6-9. PubMed ID: 8047260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.